ストックスクリーナーアプリを入手
0.4338
1.04%
-0.00455
Evogene Ltd (EVGN) 最新ニュース
How Evogene is changing the future for the pharma and agriculture markets - The Jerusalem Post
Why Did EVGN Shares Drop More Than 14% Today? - Stocktwits
Evogene | 6-K: Report of foreign private issuer (related to financial reporting) - Moomoo
Price to book forward of Evogene Ltd. – NASDAQ:EVGN - TradingView
Enterprise value to revenue forward of Evogene Ltd. – NASDAQ:EVGN - TradingView
Evogene Ltd Actuals & Estimates (NASDAQ:EVGN) - TradingView
EVGN Forecast — Price Target — Prediction for 2027 - TradingView
Evogene completes milestone in Google Cloud collaboration By Investing.com - Investing.com South Africa
Evogene completes milestone in Google Cloud collaboration - Investing.com
Evogene Announces Major Milestone in Its Coll - Moomoo
Evogene Announces Major Milestone in Its Collaboration with Google Cloud, Advancing ChemPass AI™ Toward Autonomous Small Molecule Discovery and Optimization - Nasdaq
Evogene Ltd. And Google Cloud Announces Major Milestone In Collaboration Advancing ChemPass AI Toward Autonomous Small Molecule Discovery And Optimization - marketscreener.com
Evogene Ltd (EVGN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Evogene StockWeekly review and sector context after recent Q1 update - AD HOC NEWS
Evogene Ltd (EVGN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Evogene Ltd (EVGN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Evogene Ltd (EVGN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Evogene Ltd (EVGN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Evogene Ltd (EVGN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Evogene Ltd (EVGN) Institutional Confidence - TradingKey
Evogene Ltd (EVGN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Evogene Ltd (EVGN) Valuation: PE, PB & Fair Value Analysis - TradingKey
EVGN Q1 2026 Earnings: EPS Misses Estimates by a Wide Margin Amid Weak Operating PerformancePretax Income Report - newsline.com
Evogene Showcases AI-Driven ChemPass Platform and Expanded Google Cloud Collaboration in New Investor Deck - TipRanks
Evogene (EVGN) showcases ChemPass AI drug and ag-chem discovery strategy - Stock Titan
EVGN Q1 2026 Earnings: Deep EPS Miss Raises Investor Concerns Amid Pre-Revenue StageTrough Earnings Signal - newsline.com
Biomica CEO Set to Attend JP Morgan Healthcare Week in San Franc - GuruFocus
Evogene Shares Slip 2.6% as Biotech Stock Tests Key Support Level (EVGN)Flat Correction - newsline.com
Evogene Sets Up $2.9 Million At-the-Market Share Offering With A.G.P. - The Globe and Mail
Evogene enters sales agreement for at-the-market offering of up to $2.93 million - Investing.com Australia
Evogene enters sales agreement for at-the-market offering of up to $2.93 million By Investing.com - Investing.com India
Evogene Ltd. (NASDAQ: EVGN) launches $2.93M ATM program with A.G.P. - Stock Titan
Evogene (EVGN) launches $2.93M at-the-market share offering with A.G.P. - Stock Titan
EVGN Q1 2026 Earnings: Significant EPS Miss Amid Ongoing Operational ChallengesBasic EPS Analysis - newsline.com
Evogene Q1 revenue falls to $0.3 million amid strategic shift - scanx.trade
Full Transcript: Evogene Q1 2026 Earnings CallEvogene (NASDAQ:EVGN) - Benzinga
Evogene to Present Its Pharma Division Achievements at the BIO International Convention - PR Newswire
Earnings Call Summary | Evogene(EVGN.US) Q1 2026 Earnings Conference - 富途牛牛
EVGN Stock Price, Quote & Chart | EVOGENE LTD (NASDAQ:EVGN) - ChartMill
EVGN Q1 2026 Earnings: EPS Misses Estimates Significantly, Stock DeclinesProfit Warning Alert - newsline.com
Evogene completes phase 1 trial of BMC128 cancer treatment By Investing.com - Investing.com South Africa
Evogene: Q1 Earnings Snapshot - AOL.com
Evogene (EVGN) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat
Evogene says Phase 1 clinical study of BMC128 met primary endpoint - TipRanks
Evogene completes phase 1 trial of BMC128 cancer treatment - Investing.com
Evogene Announces Successful Completion of Phase 1 Clinical Study of BMC128, a Rationally Designed Live Bacterial Product, in Combination with Nivolumab by its Subsidiary Biomica - PR Newswire
Evogene Ltd stock (IL0010831684): Shares trade quietly as investors await next catalysts - AD HOC NEWS
Evogene (EVGN) Edges Lower, Testing Key Support at $0.66Zigzag Correction - dars.gov.et
Evogene Ltd (EVGN) Holding Near Support After Modest DeclineFibonacci Arc - The Legal Advocate
EVGN Q1 2026 Earnings: Significant EPS Miss Highlights Operational ChallengesShare Repurchase Impact - The Legal Advocate
Evogene Back Under $1 as Nasdaq Deadline Approaches - Bez Kabli
Evogene (EVGN) Edges Higher: Modest Uptick Amid Support Level TestFactor Crowding - The Legal Advocate
Evogene Ltd (EVGN) Q1 2026 Earnings Call Highlights: Strategic Collaborations Amid Financial ... By GuruFocus - Investing.com Canada
EVGNEvogene Ltd Stock Price and Quote - Finviz
Evogene (EVGN) Slides 3% as Shares Test Key Support Near $0.66Put Wall - newsline.com
A. G. P. Maintains Evogene(EVGN.US) With Buy Rating, Cuts Target Price to $2.15 - Moomoo
Evogene shares decline after revenue miss despite stronger-than-expected earnings (EVGN) - MSN
Evogene Q1 2026 earnings preview - MSN
Evogene Reports Q1 2026 Results as AgPlenus Herbicide and Fungicide Programs Advance - iGrow News
1.26%
3.59%
大文字化:
|
ボリューム (24 時間):